开发新的[b]二氧化硫-2-碳胺衍生物作为先进的糖化终产品受体 (RAGE) 对手
Lisa Bonin1,2,3, Matthieu Hedouin2, Christophe Furman3
1Junia, Health and Environment, Laboratory of Sustainable Chemistry and Health, F-59000, Lille, France.
ChemMedChem
|November 30, 2025
概括
研究人员开发了新型的[b]二甲胺基衍生物,向高级糖化最终产品 (RAGE) 的受体. 这些化合物显示出对抗炎症和相关疾病的潜力,其中一个模拟物显示出与Azeliragon相似的RAGE相互作用.
科学领域:
- 药用化学 医学化学
- 衰老研究研究 衰老研究
- 分子生物学分子生物学
背景情况:
- 先进糖化最终产品 (RAGE) 激活的受体驱动慢性炎症 (炎症),与衰老和阿尔茨海默氏症和糖尿病等疾病有关.
- RAGE是健康衰老干预措施的重要治疗目标.
- 作为潜在的RAGE配体,[b]thiophene-2-carboxamide衍生物正在被探索.
研究的目的:
- 开发一种新型的合成策略,用于[b]二二胺类同类物.
- 为了确定新的RAGE配体,用于治疗衰老和与年龄有关的疾病的治疗应用.
- 为了研究合成化合物的结构-活性关系.
主要方法:
- 通过Ullmann-Goldberg合的5-arylidene-2,4-thiazolidinedione中间体合成[b]thiophene-2-carboxamide类型的类似物.
- 使用液体染色学-质谱学 (LCMS),核磁共振 (NMR) 和X射线晶体学进行表征.
- 计算研究包括密度函数理论 (DFT) 来获得机械洞察力.
- 在实验室中评估RAGE配体活性 (IC50测定).
主要成果:
- 建立了一条有效的合成路径,以获得子[b]二甲-2-碳胺类同类物.
- 通过光谱和计算分析阐明了反应机制.
- 分子3t'显示出强烈的RAGE结合亲和力 (IC50 = 13.2μM),与参考药物Azeliragon (IC50 = 13.0μM) 相比.
结论:
- 开发的合成方法提供了对新的RAGE向佐[b]二二胺基衍生物的访问.
- 化合物3t'代表了针对RAGE介导病理的进一步开发的有希望的主要候选者.
- 这项工作有助于管理炎症和相关疾病的治疗策略.
更多相关视频
相关概念视频
Glucagon-like Receptor Agonists
820
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
820
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones
565
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
565
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Oral Hypoglycemic Agents: Glinides
572
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
572


